Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab ravtansine plus sintilimab ± chemotherapy in non-squamous NSCLC
CTR20231237Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Apr 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tusamitamab ravtansine in Non-small cell lung cancer (NS-NSCLC), sponsored by Innovent Biologics. Started Apr 2023; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20231237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231237.